Reckitt Benckiser reviews all options for drugs unit
Reckitt Benckiser, the consumer goods giant, is reviewing all options for its pharmaceuticals unit, it said on Tuesday, effectively hoisting a for sale sign on its prescription medicine business.Shares in the maker of Strepsils and Gaviscon rose more than 6pc in morning trading after the Bank of America Merrill Lynch has valued the pharmaceuticals unit at about $3.2 billion (£2 billion)The business centres around the drug Suboxone, which Reckitt sells as a film that dissolves in the mouth. It is used to treat heroin addiction, but now faces increased competition from cheaper copies, or generics. In the third quarter, its ...
Source: PharmaGossip - October 23, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs
Antibiotic resistance documentary tonight in the US.
Tonight at 10:00 Eastern/9:00 Central, PBS Frontline will air a documentary about the growing threat of antibiotic-resistant bacteria.
http://boingboing.net/2013/10/22/antibiotic-resistance-watch-a.html (Source: PharmaGossip)
Source: PharmaGossip - October 23, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs
Remember
(Source: PharmaGossip)
Source: PharmaGossip - October 23, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs
GlaxoChinaGate contd. - so how's business?
GlaxoSmithKline Plc (GSK) said third-quarter sales of pharmaceuticals and vaccines in China fell 61 percent after an anti-corruption probe began there in July.
Sales of consumer health-care products in China fell 29 percent, the London-based company said today in a statement. Total revenue rose 1 percent to 6.51 billion pounds ($10.5 billion), compared with 6.64 billion pounds expected by analysts.
In China, a “dramatic decline” in Glaxo’s Seretide lung drug and Flixonase nasal spray has led to a rapid acceleration in sales of AstraZeneca Plc (AZN)’s Symbicort inhaler, Barclays Plc analysts said last week. China a...
Source: PharmaGossip - October 23, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs
It is clear that the federal government is getting a tremendous “bang for the buck” in its anti-fraud activities in health care.
There is no doubt that the federal government’s initiatives to fight health care fraud have returned large
sums of money to US taxpayers. These initiatives also improve the integrity of federal health care
programs and make a substantial contribution to their solvency. In times of constrained government
budgets, we can ill afford to have federal money wasted or stolen. It is clear that the federal government is getting a tremendous “bang for the buck” in its anti-fraud activities in health care. There
are various ways of calculating that bang for the buck, but this report makes clear that accounting for
only federal ...
Source: PharmaGossip - October 23, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs
Drug Swapping: Omnicare Pays $120M To Settle Kickback Charges
http://www.pharmalive.com/drug-swapping-omnicare-pays-120m-to-settle-kickback-charges?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+Pharmalot+%28Pharmalot%29 (Source: PharmaGossip)
Source: PharmaGossip - October 23, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs
The China Conundrum
China: An Increasingly Risky Bet for Drug MakersFor the world’s largest pharmaceutical companies, China is an increasingly critical, yet risky bet.Multinational drug companies expect sales from China to continue to grow quickly, as they did last year, accounting for 3.8% of total sales, up from 3% in 2011, according to a new report from consultancy McKinsey & Co.Agence France-Presse/Getty ImagesGlaxoSmithKline has said it expects its performance in China to take a hit from Beijing’s probe into alleged bribery by senior staff.Meanwhile, nearly half of the 50 senior pharmaceutical industry executives surveyed said th...
Source: PharmaGossip - October 22, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs
University of Minnesota must investigate suicide in psychiatric research study
The University of Minnesota must set up independent inquiry to examine what happened in clinical trial that led to the 2004 death of Dan Markingson, say scholars
Over one hundred seventy leading scholars in health law, bioethics and medical research have called on the University of Minnesota to investigate the 2004 death of a psychiatric research subject, charging that university administrators have ”refused to publicly engage in a transparent, open, and critical assessment of what went wrong in this study.” The letter, led by Trudo Lemmens, the Scholl Chair of Health Law and Policy at the University of Toronto...
Source: PharmaGossip - October 22, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs
AllTrials Update - write a letter
Dear Friends
If you live in an EU member state we need your help this week. Will you write to your country's health minister to ask your Government to support the good progress towards clinical trial transparency in the draft Clinical Trial Regulation in debates in Europe next month.
Thanks to the letters you sent to MEPs last May some very good additions were made to the draft Regulation. These new parts of the law would mean that all clinical trials taking place in Europe would have to be registered and summary results published within a year of its ending. We need to make sure that these good addit...
Source: PharmaGossip - October 22, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs
Nervous?
(Source: PharmaGossip)
Source: PharmaGossip - October 22, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs
It will never replace an espresso
(Source: PharmaGossip)
Source: PharmaGossip - October 21, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs
An Australian Affair - can anyone help with more information?
http://extras.theglobalmail.org/uploads/MedicalEthics/Reply-to-President-re-Ethics-EAG.pdf (Source: PharmaGossip)
Source: PharmaGossip - October 21, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs
Medical Ethics Under The Knife. By Clare Blumer
It took three years to complete. Professors, physicians and philosophers collaborated with Australian and New Zealand transparency and ethics compadres, labouring on the latest edition of Guidelines for ethical relationships between health professionals and industry.This document serves predominantly as the ethical guidebook for fellows of the Royal Australasian College of Physicians (RACP), and in its 20-year history has been adopted as the benchmark template by comparable medical professional bodies in Australia and around the world. The 4th edition is stricter in its recommendations than that produced in 2006&...
Source: PharmaGossip - October 21, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs
The Global Mail Drug Money Series
http://www.theglobalmail.org/features/in/drug-money/?utm_source=Custom+sidebar&utm_medium=Homepage&utm_campaign=Custom+sidebar (Source: PharmaGossip)
Source: PharmaGossip - October 21, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs
Australasian college of physicians sacks its ethics committee
The Royal Australasian College of Physicians has sacked its own ethics committee just days after the committee produced strict new guidelines on doctors’ ties to industry.The college has also provoked an outcry by refusing to release its guidelines for public consultation, opting for an internal process instead.The draft Guidelines for Ethical Relationships Between Health Professionals and Industry had strengthened the already tough, pro-transparency stance of previous editions. Among its recommendations it labelled doctors’ use of drug samples and starter packs as “inappropriate,” it said, given that the...
Source: PharmaGossip - October 21, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs
